Product Information
CANDESARTAN-HYDROCHLOROTHIAZIDE 16-12.5 MG TB is a generic product labeled by Mylan Pharmaceuticals Inc., priced at $0.9753 per EA under NDC 00378300177. Its NADAC has been published 665 times since Nov 28, 2013.
FDA first approved this application on Dec 4, 2012. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the candesartan cilexetil and hydrochlorothiazide market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
CANDESARTAN-HYDROCHLOROTHIAZIDE 16-12.5 MG TB
candesartan cilexetil and hydrochlorothiazideStrength
16; 12.5 mg/1; mg/1
Manufacturer
Mylan Pharmaceuticals Inc.NDC
00378300177
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
8/19/2026
Active Ingredients
CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDEApproval Type
Generic (ANDA)
FDA Application
ANDA090704FDA Approved
12/4/2012
TE Code
AB
On Market Since
12/4/2012
Pharmacological Classes
Price Statistics
The NADAC for CANDESARTAN-HYDROCHLOROTHIAZIDE 16-12.5 MG TB has been published 665 times since Nov 28, 2013, and over the history we have for it it has declined 37.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.9753 per EA |
|---|---|
| All-time high | $3.6028 (Mar 15, 2017) |
| All-time low | $0.6502 (Nov 20, 2024) |
| 52-week high | $1.0596 |
| 52-week low | $0.7758 |
| Median price | $2.0633 |
| Average price | $2.0243 |
| Largest weekly change | +59.6% (Jul 20, 2016) |
| Weeks tracked | 665 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of CANDESARTAN-HYDROCHLOROTHIAZIDE 16-12.5 MG TB?
The current National Average Drug Acquisition Cost (NADAC) for CANDESARTAN-HYDROCHLOROTHIAZIDE 16-12.5 MG TB, manufactured by Mylan Pharmaceuticals Inc., is $0.9753 per EA (NDC 00378300177), effective Aug 19, 2026.
How has the price of CANDESARTAN-HYDROCHLOROTHIAZIDE 16-12.5 MG TB changed over time?
Over the history we have for it, the NADAC for CANDESARTAN-HYDROCHLOROTHIAZIDE 16-12.5 MG TB has declined 37.1%. It has been tracked across 665 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for CANDESARTAN-HYDROCHLOROTHIAZIDE 16-12.5 MG TB?
Since Nov 28, 2013, the NADAC for CANDESARTAN-HYDROCHLOROTHIAZIDE 16-12.5 MG TB has ranged from a low of $0.6502 (Nov 20, 2024) to a high of $3.6028 (Mar 15, 2017), with a median of $2.0633 per EA.
Are there cheaper alternatives to CANDESARTAN-HYDROCHLOROTHIAZIDE 16-12.5 MG TB?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as CANDESARTAN-HYDROCHLOROTHIAZIDE 16-12.5 MG TB in a comparable dosage form, but none are currently priced below it.
Who manufactures CANDESARTAN-HYDROCHLOROTHIAZIDE 16-12.5 MG TB?
CANDESARTAN-HYDROCHLOROTHIAZIDE 16-12.5 MG TB (NDC 00378300177) is labeled by Mylan Pharmaceuticals Inc., and CMS classifies it as a generic product.